|
||
|
| Home |  |
Firm Description | |
Sectors Covered | |
Completed Transactions | |
Testimonials | |
Principals | |
M&A Report and Publications |
|
Contact Us | |
| Acquiring Party | Inverness Medical Innovations, Inc. (Amex:IMA), a provider of rapid diagnostic products for women’s health and chronic disease self-management. |
|---|---|
| Transferring Party | Cholestech Corporation (Nasdaq:CTEC), a leading provider of diagnostic tools and information for risk assessment and therapeutic monitoring of heart disease and inflammatory disorders. |
| Sector | Diagnostics |
| Date | September 13, 2007 |
| Analysis Provides Inverness with the ability to manage cardiac conditions, plus a large installed base of Cholestech systems in physicians' offices. Cross selling opportunities into each others customer bases, plus Cholestech synergizes with Inverness' new product pipeline of cardiac markers. Stock for stock deal value - $326.3m, on sales of $69.5m (4.7x) and EBITDA of $14.3m (22.8x). | |
The Walden Group is a leading healthcare investment banking firm specializing in mergers, acquisitions and strategic transactions. It also invests its own funds and, together with its expert operational partners, provides value-added services to help special companies reach critical milestones. This information is copyright © 2004-2007 The Walden Group, Inc. This information is provided as a service to the public but remains the intellectual property of The Walden Group, Inc and may not be reproduced in any manner without the written permission of The Walden Group, Inc. The information contained in the transactions table was derived from publicly available and other sources. Transaction analysis and other information are based, in part, upon public comments, Walden Group research and judgments, and reporting and research of others. The information is not intended to be relied upon as pronouncements by the transaction participants or for any other reason. | |